循环肿瘤DNA指导转移性结直肠癌多发小肺结节治疗策略的前瞻性队列研究
该前瞻性队列研究纳入70例仅伴小肺结节(≤2 cm)的转移性结直肠癌患者,按结节大小分队列1(≤1 cm)和队列2(1-2 cm),用肿瘤知情ctDNA动态监测。基线ctDNA阳性仅在队列1与更短PFS相关,全身化疗较局部治疗显著提高ctDNA清除率,ctDNA清除与更长PFS相关,纵向持续阴性者PFS优于总体人群,且ctDNA可比影像学提前中位5.5个月预测肺外转移。
要点
- 基线ctDNA阳性仅在≤1 cm肺结节患者中与更短PFS显著相关。
- 全身化疗的ctDNA清除率显著高于单纯局部治疗(63.2% vs 12.5%)。
- ctDNA动态监测可提前中位5.5个月预警肺外转移,肺外转移者PFS更差。
核心结论
- 纵向ctDNA监测可能为仅伴小肺结节的mCRC患者提供预后信息并帮助识别肺外进展。
- 这些探索性发现需前瞻性验证后才能指导临床治疗决策。
研究设计与样本
- 前瞻性队列研究,纳入70例仅伴小肺结节(≤2 cm)的转移性结直肠癌患者。
- 按结节大小分为队列1(≤1 cm)和队列2(1-2 cm)。
- 采用肿瘤知情ctDNA检测,时间点为基线、可选局部治疗或全身化疗后30天,随后每3个月一次至24个月或疾病进展。
- 主要终点为无进展生存期(PFS)。
主要发现
- 基线ctDNA阳性率在队列1为35.5%,在队列2为66.7%。
- 队列1中基线ctDNA阳性与更短PFS显著相关(中位PFS 3.2个月 vs 9.2个月,P=0.013),队列2中未见此关联。
- 全身化疗较单纯局部治疗带来五倍更高的ctDNA清除率(63.2% vs 12.5%,P=0.033)。
- ctDNA清除与更长中位PFS相关(12.6个月 vs 6.8个月,P=0.038)。
- 纵向持续ctDNA阴性者PFS显著长于总体人群(中位PFS未达到 vs 9.2个月,P=0.012)。
临床怎么用
- 对仅伴小肺结节的mCRC患者可考虑纵向ctDNA监测以辅助预后分层和肺外转移预警。
- ctDNA清除情况可作为评估全身化疗疗效的分子指标之一。
- 目前证据尚属探索性,不应仅依据ctDNA结果改变临床治疗决策。
局限性
- 研究为探索性设计,样本量70例,结论需前瞻性验证。
- 原文未报告随机化或盲法等信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Small pulmonary nodules (SPNs ≤ 2 cm) in metastatic colorectal cancer (mCRC) had heterogeneous biology and no evidence-based treatment algorithms. Circulating tumor DNA (ctDNA) can detect molecular residual disease (MRD) but lacks prospective validation for treatment guidance in this setting. METHODS: 70 mCRC patients with exclusively SPNs were assigned to Cohort 1 (≤1 cm) and Cohort 2 (1-2 cm). Tumor-informed ctDNA was detected at baseline, 30 days after optional local treatment or systemic chemotherapy, then every 3 months for 24 months or until progression. Primary endpoint was progression-free survival (PFS). RESULTS: Baseline ctDNA positivity was 35.5% in Cohort 1 and 66.7% in Cohort 2. In Cohort 1, baseline ctDNA positivity significantly correlated with shorter PFS (median PFS: 3.2 months vs. 9.2 months, P = 0.013), which was not seen in Cohort 2. Systemic chemotherapy was associated with a five-fold higher ctDNA clearance than local treatment alone (63.2 % vs. 12.5 %, P = 0.033). ctDNA clearance was associated with longer median PFS (12.6 months vs. 6.8 months, P = 0.038). Longitudinally, patients with consistently negative ctDNA had significantly longer PFS than the overall population (median PFS: not reached vs. 9.2 months, P = 0.012). ctDNA better predicted extrapulmonary metastases with a median lead time of 5.5 months (range, 2.8-9.2 months) preceding radiographic confirmation and extrapulmonary metastases predicted poorer PFS than intrapulmonary spread (median PFS: 3.5 months vs. 9.9 months, P = 0.005). CONCLUSIONS: Longitudinal ctDNA monitoring may provide prognostic information and help identify extrapulmonary progression in mCRC patients with SPNs. These exploratory findings require prospective validation before informing clinical treatment decisions.
引用
- Chang J, Li Y, Mo S, et al. Circulating tumor DNA-guided therapeutic strategies for metastatic colorectal cancer patients with multiple small pulmonary-limited nodules: A prospective cohort study. Eur J Cancer. 2026. PMID: 42962410. doi:10.1016/j.ejca.2026.117793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。